By Iain Gilbert
Date: Thursday 06 Nov 2025
(Sharecast News) - Drugmaker AstraZeneca reiterated its full-year guidance on Thursday as it posted a third-quarter earnings beat, driven by solid sales of its cancer, heart and kidney disease drugs.
| AstraZeneca's Koselugo receives EU approval | 28-Oct-2025 | ShareCast |
| Astrazeneca's Tezspire secures EU approval | 22-Oct-2025 | ShareCast |
| AstraZeneca lupus treatment gets EU approval | 20-Oct-2025 | ShareCast |
| Deutsche Bank downgrades AstraZeneca to 'sell' | 16-Oct-2025 | ShareCast |
| AstraZeneca to cut US drug prices in key White H... | 13-Oct-2025 | ShareCast |
| 9M and Q3 2025 results | 06-Nov-2025 | 07:00 | RNS |
| Result of General Meeting | 03-Nov-2025 | 16:00 | RNS |
| Total Voting Rights | 03-Nov-2025 | 15:00 | RNS |
| Director Declaration | 28-Oct-2025 | 07:05 | RNS |
| Koselugo (selumetinib) approved in the EU | 28-Oct-2025 | 07:00 | RNS |
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 12,780.00p |
| Change Today | 330.00p |
| % Change | 2.65 % |
| 52 Week High | 12,994.00p |
| 52 Week Low | 9,667.00p |
| Volume | 1,560,593 |
| Shares Issued | 1,550.71m |
| Market Cap | £198,181m |
| Beta | 1.33 |
| RiskGrade | 123 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 10 |
| Buy | 13 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Latest | Previous | |
|---|---|---|
| 1st Interim | 2nd Interim | |
| Ex-Div | 07-Aug-25 | 20-Feb-25 |
| Paid | 08-Sep-25 | 24-Mar-25 |
| Amount | 103.00¢ | 210.00¢ |
| Time | Volume / Share Price |
| 14:52 | 24 @ 12,778.00p |
| 14:52 | 38 @ 12,778.00p |
| 14:52 | 24 @ 12,778.00p |
| 14:52 | 86 @ 12,782.00p |
| 14:52 | 28 @ 12,782.00p |
You are here: research